AptarGroup

At the Wells Fargo Healthcare Conference, AptarGroup under new CEO Gael Touya highlighted execution as a priority and confirmed solid growth in its pharma business and in injection systems. The company sees long‑term opportunities in intranasal delivery, GLP‑1 research and OTC switches, but conceded operational issues in the North American beauty segment and production/maintenance shortfalls. A destocking of emergency medicines hit the first half by $65–70 million, is expected to be mostly resolved by Q4 and should improve the margin base for 2027. » More on de.investing.com

Dermalogica is using AptarGroups' NeoDropper autoload pipette technology for its new FutureCode Booster serum. The system combines a twist-and-press delivery mechanism with an automatic reload system. The design is intended to reduce breakage risk, minimize product loss and was praised by consumers for dosing performance and ease of use. The product launch expands the existing partnership with Aptar, which previously supplied recyclable dosing solutions to Dermalogica. » More on de.investing.com

AptarGroup announced a quarterly cash dividend of $0.48 per share, payable August 20, 2026 to shareholders of record on July 30, 2026. According to the data, the company has increased its dividend for 33 consecutive years; the current dividend yield is 1.49%. AptarGroup is rated as undervalued and will hold a conference call on July 31, 2026 to discuss Q2 results. » More on de.investing.com

AptarGroup has appointed Aditya J. Gandhi as vice president and chief accounting officer, effective June 8, 2026. Gandhi will report to Vanessa Kanu and succeeds Daniel Ackerman, who will take on a different leadership role within the finance organization. He will receive a one-time sign-on bonus of USD 105,000 and a one-time equity award with a grant-date value of USD 715,000; his career most recently includes positions at Sonoco Products Company, WestRock and General Electric. » More on de.investing.com

Stephan Tanda will retire as CEO on Sept. 1, 2026 and Gael Touya, head of Aptar Pharma, will succeed him; Tanda will serve as adviser through year-end and is expected to leave the board at year-end. Shareholders elected four directors, approved executive compensation on an advisory basis and ratified PricewaterhouseCoopers as auditor. Reported 2025 sales rose 5% to $3.8 billion with Pharma leading growth, and the company returned $486 million to shareholders through buybacks and dividends. Management said Q1 2026 reported sales increased 11% and reiterated unchanged long-term targets, including a 4–7% core sales growth range and a 21–23% adjusted EBITDA margin goal. » More on finance.yahoo.com